![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Gilead Sciences |
Information provided by: | Gilead Sciences |
ClinicalTrials.gov Identifier: | NCT00423202 |
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
Condition | Intervention | Phase |
Pulmonary Arterial Hypertension |
Drug: ambrisentan |
Phase III |
Genetics Home Reference related topics: | pulmonary arterial hypertension |
MedlinePlus related topics: | High Blood Pressure |
Drug Information available for: | Ambrisentan |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. |
Estimated Enrollment: | 186 |
Study Start Date: | December 2003 |
Estimated Study Completion Date: | October 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Related Info 
![]()   |
Study ID Numbers: | AMB-321, ARIES-2 |
First Received: | January 17, 2007 |
Last Updated: | January 17, 2007 |
ClinicalTrials.gov Identifier: | NCT00423202 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
![]() |